openPR Logo
Press release

Developments in Gene Therapy for Ocular Diseases

08-25-2022 04:17 PM CET | Health & Medicine

Press release from: SAE Media Group

The Ophthalmic drugs industry continues to expand year on year, with an ageing population there is continual demand for advancements in ophthalmic treatments. This year's Ophthalmic Drugs Conference will have a key focus on gene therapy and artificial intelligence with developments on the latest drug pipelines and clinical trials.

The conference will convene on 21 - 22 November 2022 in London, UK, this year attendees will hear from industry giants about the developments being made in the ophthalmics and gene therapy field.

Interested parties can register at http://ophthlamicdrugs.com/PROR - register by 30 September to save £100.

The 5th annual conference will have a more in-depth discussion about the Developments in Gene Therapy for Ocular Diseases, with presentations and keynote speakers.

Use of Antisense Oligonucleotides for the Treatment of Inherited Retinal Diseases
•Antisense oligonucleotides have shown much promise in Ph1/2 Clinical Trials in LCA10 and Usher's Syndrome
•Lessons learned from Ph 2/3 trial with Sepofarsen for LCA10
•Latest trial data from Interim Analyses for Ultevursen for Usher's syndrome and non-syndromic Retinitis Pigmentosa
Led by: Aniz Girach, Chief Medical Officer, ProQR Therapeutics

Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy
•LHON, a rare disease with high unmet medical need
•Development of Lumevoq Gene Therapy to treat ND4 LHON patients Developments in Gene Therapy for Ocular Diseases Drug Delivery Regulatory pathways
•Key learnings from recent data
Led by: Magali Taiel, Chief Medical Officer, Gensight Biologics

Ocular Inflammation associated with Gene and Cell Therapy
•Immune privilege and the eye
•Inflammation and gene therapy
•Inflammation and cell-based therapy
•What to look for….
Led by: Virginia Calder, Professor of Ocular
Immunology, University College London
Strengthening the Therapeutic Landscape for Inherited Retinal Diseases Using Genome Editing with AAV Vectors & CRISPR/Cas9 Technologies
•Expanding on the clinical development of novel gene therapies including SPVN06
•The benefits of designing gene therapies to act independently of the causative gene mutation
•An introduction to new clinical trials and future workings
Led by: Daniel Chung, Chief Medical Officer, Sparing Vision

To find out more about the line - up of the esteemed speakers for the conference and to download a complimentary brochure please visit http://ophthlamicdrugs.com/PROR

For sponsorship enquiries contact Andrew Gibbons on +44 (0) 20 7827 6156 or email: agibbons@smi-online.co.uk

For media enquiries or a press pass contact Marketing, Simi Sapal on +44 (0) 20 7827 6162 or email ssapal@smi-online.co.uk

Ophthalmic Drugs
21-22 November 2022
London, UK
#OphthalmicDrugs
Sponsor: The Technology Partnership | Celanese
http://ophthlamicdrugs.com/PROR

India House, 45 Curlew Street

--- ENDS ---

About SAE Media Group Conferences:
SAE Media Group Conferences connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges. Our key events focus on Defence and Aerospace, Pharmaceutical and Medical. Each year we bring together over 5,000 senior business professionals at our conferences. http://www.smgconferences.com
SAE Media Group (SMG), a subsidiary of SAE International, reports the latest technology breakthroughs and design innovations to a global audience of nearly 1,000,000 engineers, researchers, and business managers. SMG provides critical information these professionals need to develop new and improved products and services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Developments in Gene Therapy for Ocular Diseases here

News-ID: 2716040 • Views:

More Releases from SAE Media Group

Launch of the C-UAS Hub Report 2025: Countering the Threat: A Comprehensive Review of National C-UAS Programs
Launch of the C-UAS Hub Report 2025: Countering the Threat: A Comprehensive Revi …
SAE Media Group, renowned for its sell-out Counter UAS Conferences and owner of the C-UAS Hub, is excited to announce the release of its first-ever C-UAS Hub Report 2025, titled "Countering the Threat: A Comprehensive Review of National C-UAS Programs." As drones continue to play an increasingly prominent role in both military and civilian sectors, the demand for effective Counter UAS solutions is growing rapidly. NATO allies are making significant investments
How MilSatCom has transformed warfare and continues to shape the battlefield.
How MilSatCom has transformed warfare and continues to shape the battlefield.
The advancement of space-based communications technologies, including the ever-increasing presence of military satellites for electronic and signals intelligence purposes, has dramatically changed the way wars are fought down on Earth. From the launch of the first satellite communications network to the cutting-edge technology that is still in development, below we take a look at how far MilSatCom has come. A brief history of MilSatCom The first military communications satellites were launched by the
Conference Co-chairs from Merck & AstraZeneca invitation to join 3D Cell Culture
Conference Co-chairs from Merck & AstraZeneca invitation to join 3D Cell Culture
SAE Media Group reports: Conference co-chairs invite delegates to join the anticipated 6th Annual 3D Cell Culture Conference SAE Media Group is delighted to announce the return of successful 3D Cell Culture Conference for its 6th year, taking place on 8 and 9 February 2023 in London, UK. The 2023 Conference theme is on exploring the implementation of complex in-vitro models for drug development Visit the website at http://www.3d-cellculture.com/PR2 to find out
Exploring the Implementation of Complex In-vitro Models for Drug Development
Exploring the Implementation of Complex In-vitro Models for Drug Development
SAE Media Group reports: Agenda and speaker overview released for the 6th Annual 3D Cell Culture Conference, London, UK SAE Media Group is delighted to announce the return of successful 3D Cell Culture Conference for its 6th year, taking place on 8 and 9 February 2023 in London, UK. 3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years, with the global 3D Cell Culture market predicted to

All 5 Releases


More Releases for Gene

Competitive and Opportunities Analysis of Gene Therapy Market of Gene Therapy Ma …
Global Gene Therapy Market accounted for US$ 2.05 billion in 2020 and is estimated to be US$ 12.29 billion by 2030 and is anticipated to register a CAGR of 19.8%. Gene therapy means fixing a working gene to an individual who features a damaged gene. The European Commission has approved this method for one particular treatment. The treatment by the merchandise Glybera uses an epidemic to infect muscle cells with
Genetic Testing Market Size by Growth Opportunities, Top Key Players: GeneDx, In …
Genetic Testing Market Report provides an in-depth analysis of the overall market, The ripple effect of Coronavirus-Covid19 on the market needs to become part of strategy discussions to emerge strong. The report focuses on major key players, production details, their application, countries and also analyzes the global and key regions market potential and advantage, opportunity, and challenge, restraints, and risks. The Top players Covered in report are GeneDx, Invitae, Pathway Genomics,
Gene Synthesis Market by Top Manufacturers - Gene script, Gene Art (Thermofische …
The "Gene Synthesis Market" report Added by "Big Market Research", enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies. In the Gene Synthesis Market 2018 research report professionals describe the different facets of the industry with a specific goal
Gene Therapy Market, by Gene Therapy Type Germline Gene Therapy and Somatic Gene …
Genes are composed of deoxyribonucleic acid (DNA), which contains essential information for producing proteins that are crucial for the optimal functioning of the body. Genetic disorder is the result of gene mutations in which proteins are made incorrectly. Gene therapy is intended to introduce healthy gene into damaged cells to counteract for abnormal genes or to make a protein of interest. Mutated gene causes missing of the important protein, with
Gene Editing Market : A Market Study On Gene Editing And Cancer Therapy Techniqu …
Global Gene Editing Market Precision Business Insights (PBI) in its report titled “Global Gene Editing Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2017 and Forecast 2018-2027” assesses the market performance over 2018-2027. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Gene editing or Genome editing is
Direct-to-consumer Genetic Testing Market: Top Players - Gene By Gene, MyHeritag …
Latest industry research report on: Global and United States Direct-to-consumer Genetic Testing Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts This report studies the Direct-to-consumer Genetic Testing market status and outlook of global and major regions, from angles of players, regions, product and end Application/industries; this report analyzes the top players in global and major regions, and splits the Direct-to-consumer Genetic Testing market by product